Patents by Inventor Thomas Welge

Thomas Welge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Imidazole compounds used as phosphodiesterase VII inhibitors
    Patent number: 6884800
    Abstract: Imidazole compounds of the formula I in which R1 and R2, independently of one another, each denote A1, OA1, SA1 or Hal, A1 denotes H, A, alkenyl, cycloalkyl or alkylenecycloalkyl, A denotes alkyl having 1-10 carbon atoms, Hal denotes F, Cl, Br or I, and X denotes O, S, SO or SO2, and their physiologically acceptable salts and/or solvates, as phosphodiesterase VII inhibitors, and their use for the preparation of a medicament.
    Type: Grant
    Filed: October 31, 2000
    Date of Patent: April 26, 2005
    Assignee: Merck Patent Gesellschaft mit Beschrankter Haftung
    Inventors: Hans-Michael Eggenweiler, Rochus Jonas, Michael Wolf, Michael Gassen, Thomas Welge
  • Use of type 4 phosphodiesterase inhibitors in myocardial diseases
    Publication number: 20050070529
    Abstract: The invention relates to the use of type 4 phosphodiesterase inhibitors to treat myocardial diseases.
    Type: Application
    Filed: January 15, 2002
    Publication date: March 31, 2005
    Applicant: Merk Pantent GmbH
    Inventors: Arne Sutter, Thomas Ehring, Thomas Welge, Klause Minck, Claudia Wilm, Michael Gassen, Hans-Michael Eggenweiler, Michael Wolf, Pierre Schelling, Norbert Beier, Joachim Leibrock
  • Pyrrole derivatives as phosphodiesterase VII inhibitors
    Patent number: 6737436
    Abstract: Compounds of the formula I in which R1 and R2, independently of one another, each denote H, A, OA, SA or HaI, R3 denotes H or A, R4 denotes A or NH2, R5 denotes H, NH2, NHA or NA2, A denotes alkyl having 1 to 10 carbon atoms, alkenyl, cycloalkyl or alkylenecycloalkyl, Hal denotes F, Cl, Br or I, and their physiologically acceptable salts and/or solvates, as phosphodiesterase VII inhibitors.
    Type: Grant
    Filed: May 3, 2002
    Date of Patent: May 18, 2004
    Assignee: Merck Patent GmbH
    Inventors: Hans-Michael Eggenweiler, Rochus Jonas, Michael Wolf, Michael Gassen, Thomas Welge
  • Imidazopyridine derivatives as phosphodiesterase VII inhibitors
    Patent number: 6613778
    Abstract: Compounds of the formula I in which R1 denotes CONR4R5, R2 denotes H or A, R4 and R5, independently of one another, each denote H or A1, R3 denotes Hal, Hal denotes F, Cl, Br or I, A denotes alkyl having 1-4 carbon atoms, A1 denotes alkyl having 1-10 carbon atoms, X denotes alkylene having 1-4 carbon atoms, in which an ethylene group may also be replaced by a double or triple bond, and their physiologically acceptable salts and/or solvates, as phosphodiesterase VII inhibitors, and their use for the preparation of a medicament.
    Type: Grant
    Filed: May 3, 2002
    Date of Patent: September 2, 2003
    Assignee: Merck Patent Gesellschaft mit beschränkter Haftung
    Inventors: Hanse-Michael Eggenweiler, Karl-August Ackermann, Rochust Jonas, Michael Wolf, Michael Gassen, Thomas Welge
  • Isoxazole derivatives to be used as phosphodiesterase VII inhibitors
    Patent number: 6531498
    Abstract: The invention relates to compounds of formula I and to their physiologically acceptable salts and solvates which act as phosphodiesterse VII inhibitors and are thus useful for the treatment of allergic disorders, asthma, chronic bronchitis, atopic dermatitis, psoriasis and other skin disorders, inflammatory disorders, autoimmune diseases, rheumatoid arthritis, multiple sclerosis, Crohn's disease, diabetes mellitus or ulcerative colitis, osteoporosis, transplant rejection reactions, cachexia, tumor growth, tumor metastases, sepsis, memory disturbances, atherosclerosis and AIDS.
    Type: Grant
    Filed: May 3, 2002
    Date of Patent: March 11, 2003
    Assignee: Merck Patentgesellschaft
    Inventors: Hans-Michael Eggenweiler, Rochus Jonas, Michael Wolf, Michael Gassen, Thomas Welge